Sanofi CEO Paul Hudson has $23B burning a hole in his pocket. And here are some hints on how he plans to spend that
Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.
After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.